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In addition to its effects in the hypothalamus to control body weight, leptin is involved in the regulation of neuronal function,
development and survival. Recent ﬁndings have highlighted the neuroprotective effects of leptin against ischemic brain injury;
however,todate,littleisknownabouttheroleperformedbythesignaltransducerandactivatoroftranscription(STAT)-3,amajor
mediator of leptin receptor transduction pathway in the brain, in the beneﬁcial effects of the hormone. Our data demonstrate that
systemic acute administration of leptin produces neuroprotection in rats subjected to permanent middle cerebral artery
occlusion(MCAo),asrevealedbyasigniﬁcantreductionofthebraininfarctvolumeandneurologicaldeﬁcitupto7daysafterthe
induction of ischemia. By combining a subcellular fractionation approach with immunohistoﬂuorescence, we observe that
neuroprotection is associated with a cell type-speciﬁc modulation of STAT3 phosphorylation in the ischemic cortex. The early
enhancement of nuclear phospho-STAT3 induced by leptin in the astrocytes of the ischemic penumbra may contribute to a
beneﬁcial effect of these cells on the evolution of tissue damage. In addition, the elevation of phospho-STAT3 induced by leptin
in the neurons after 24h MCAo is associated with an increased expression of tissue inhibitor of matrix metalloproteinases-1
in the cortex, suggesting its possible involvement to the neuroprotection produced by the adipokine.
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Leptin is a 16-kDa protein hormone, secreted primarily by
the white adipose tissue in direct proportion to body fat stores,
which functions in the hypothalamus to regulate the body
weight by reducing food intake and by increasing energy
expenditure. Leptin exerts multiple effects on the reproduc-
tion, neuroendocrine system, immune reactions, and recent
studies implicate this protein in the regulation of neuronal
function,
1 development
2 and survival.
3
Leptin receptors (ObRs) originate from alternative splicing
of a single mRNA and are classiﬁed as the short (ObRa, c, d, f),
long (ObRb) and soluble (ObRe) forms. The long isoform
is abundantly expressed in the hypothalamus and is thought
to mediate many of the physiological actions of leptin, in
particular those controlling feeding and energy balance;
whereas the short form appears to mediate the transfer of
leptin from the periphery through the blood brain barrier.
4
ObRs have also been found in several other regions of the
mammalian brain, being expressed both in the neurons and in
glial cells.
5–7
ObR is a member of the class I cytokine receptor super-
family.
8Upon leptin binding, ObRactivates the Janus tyrosine
kinase (JAK)-2, which in turn recruits signal transducer and
activator of transcription (STAT)-3 proteins to the receptor.
Upon phosphorylation, STAT3 dimerizes and translocates to
the nucleus where it regulates the expression of target
genes.
9 Alternative downstream targets of leptin signaling
include extracellular signal-regulated kinase (ERK) 1/2 and
phosphatidylinositol 3-kinase (PI3K), which subsequently
activates the prosurvival factor protein kinase B/Akt. These
signaling pathways underlie the neurotrophic and neuro-
protective roles of leptin.
3
Recent ﬁndings have highlighted the neuroprotective
effects of leptin against ischemic injury both in vitro and
in vivo.
5,10 Although various mechanisms, including the
activation of ERK1/2, Akt and c-Rel, have been suggested
tounderlie the beneﬁcialeffectsof thehormone,littleisknown
about the role of STAT3, a major mediator of ObR transduc-
tion pathway in the brain.
9 Thus, in order to unravel the role of
thismediatorinleptin-inducedneuroprotectioninstroke,here,
we provide a comprehensive evaluation of STAT3 activa-
tion by combining a subcellular fractionation approach with
immunohistoﬂuorescence. Our data demonstrate that leptin
Received 17.10.11; accepted 26.10.11; Edited by G Melino
1Department of Pharmacobiology and University Consortium for the Study of Adaptive Disorders and Head Pain, Section of Neuropharmacology of Normal and
Pathological Neuronal Plasticity, University ofCalabria, Rende (CS), Italy;
2IRCCS ‘National Neurological Institute C Mondino’ Foundationand UniversityConsortium for
the Study of Adaptive Disorders and Head Pain, University of Pavia, Pavia, Italy and
3Department of Health Sciences, University ‘Magna Graecia’ of Catanzaro,
Catanzaro, Italy
*Corresponding author: D Amantea, Department of Pharmacobiology, University of Calabria, via P. Bucci, Ed. Polifunzionale, 87036, Rende (CS), Italy.
Tel: þ39 0984 493189; Fax: þ39 0984 493270; E-mail: amantea@unical.it
Keywords: astrocytes; leptin; neuroinﬂammation; STAT3; stroke
Abbreviations: ERK, extracellular signal-regulated kinase; GFAP, glial ﬁbrillary acidic protein; JAK, Janus tyrosine kinase; MCAo, middle cerebral artery occlusion;
NeuN, neuronal nuclei; ObR, leptin receptor; OGD, oxygen–glucose deprivation; p-Akt, phospho-Akt; PBS, phosphate-buffered saline; PI3K, phosphatidylinositol
3-kinase; p-STAT3, phospho-STAT3; STAT-3, signal transducer and activator of transcription-3; TIMP-1, tissue inhibitor of matrix metalloproteinases-1;
TTC, triphenyltetrazolium chloride
Citation: Cell Death and Disease (2011) 2, e238; doi:10.1038/cddis.2011.125
& 2011 Macmillan Publishers Limited All rights reserved 2041-4889/11
www.nature.com/cddisexerts a signiﬁcant reduction of the brain infarct damage and
neurological deﬁcit induced by permanent focal cerebral
ischemia in the rat, and this is associated with a cell
type-speciﬁc modulation of STAT3 phosphorylation in the
ischemic cortex.
Results
Systemic administration of leptin signiﬁcantly reduced the
brain infarct damage produced by 24h permanent middle
cerebral artery occlusion (MCAo) in the rat. Neuroprotection
was observed when leptin was administered subcutaneously
(s.c.) at the dose of 1mg/kg, 3h before MCAo (Figure 1a).
By contrast, the same dose of leptin administered 6h or
immediately before the induction of ischemia produced
only a slight, not statistically signiﬁcant, reduction of infarct
volumeascomparedwithvehicle-treatedanimals(Figure 1a).
Administration of a lower dose of leptin (0.1mg/kg, 3h
before MCAo) resulted in an infarct volume (534.9±
56mm
3, n¼3) comparable to that observed in vehicle-
injected (phosphate-buffered saline (PBS), 1ml/kg s.c.)
animals (508.1±35.9mm
3, n¼5).
Brain damage produced by MCAo in the animals treated
with vehicle (PBS, 1ml/kg s.c.) involved the brain regions
supplied by the middle cerebral artery, including the striatum
and the frontoparietal cortex (Figure 1b). Administration of
leptin (1mg/kg, s.c., 3h before MCAo) signiﬁcantly reduced
ischemicbraindamageinperifocalregionssuchasthemedial
caudate–putamenandthemotorcortex(Figures1bandc).To
exclude the possibility that neuroprotection by leptin was due
to altered cerebral blood perfusion, we have monitored
regional cerebral blood ﬂow (CBF) and found no difference
between vehicle- and leptin-treated animals. Reduction of
cortical CBF, as monitored for 10min after the induction of
MCAo was 21±3% of basal in vehicle-injected animals and
18±3% of basal in rats treated with leptin.
To determine whether neuroprotection by leptin persists
over time, we have measured the brain infarct volume and
neurological deﬁcit up to 7 days after MCAo. A signiﬁcant
reduction of the brain infarct volume was observed in
rats treated with leptin (1mg/kg, s.c., 3h before MCAo) as
determined either 3 or 7 days after permanent ischemia
(Figure 2a). Neuroprotection was accompanied by a signi-
ﬁcant reduction of neurological deﬁcit 3, 4 and 7 days after
ischemia, as compared with vehicle-treated rats (Figure 2b);
whereas the reduction of body weight was not affected by
leptin treatment (Figure 2c).
Western blotting analysis of phosphorylated STAT3
expression in cortical brain tissue homogenates shows
that phospho-STAT3 (p-STAT3) immunoreactivity is faintly
detectable in the cerebral cortex after sham operation
(Figure 3). Faint immunoreactivity for p-STAT3 was also
detected in the contralateral, non-ischemic, cerebral cortex
whereas it signiﬁcantly (Po0.001) increased in the ipsilateral,
ischemiccortex ofratssubjected to3h MCAo (Figure 3).After
24h ischemia, STAT3 phosphorylation further increased in
the ipsilateral cortex along with enhanced immunoreactivity
also occurring in the contralateral cortex. STAT3 phosphory-
lation was not affected by leptin treatment 3h after MCAo;
however, levels of p-STAT3 in the ischemic cortex tended to
be higher in leptin-treated rats 24h after permanent ischemia
and statistically signiﬁcant (Po0.05) differences between
contralateral and ipsilateral p-STAT3 were, indeed, observed
only in rats treated with leptin (Figure 3).
Western blotting analysis of phosphorylated Akt documen-
ted quite similar levels of phospho-Akt (p-Akt) immunoreac-
tivity in cortical homogenates from contralateral side and
sham-operated animals (Figure 3). Ischemic insult increased
levels of Akt phosphorylation in the cortex 3h after MCAo
(Figure 3). Akt phosphorylation in the ischemic cortex was
not affected by leptin treatment 3h after MCAo; however, a
statistically signiﬁcant (Po0.05) increase of Akt phosphory-
lation versus ipsilateral cortex of sham-operated rats was
observed only in leptin-treated animals (Figure 3). In contrast
to STAT3 phosphorylation, levels of p-Akt no further
increased 24h after MCAo; indeed, they were lower than
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Figure1 Systemic(s.c.)administrationofleptinatthedoseof1mg/kg,3hbeforetheinductionofischemia,signiﬁcantlyreducesthebraininfarctvolumeproducedby24h
permanent MCAo. By contrast, the same dose of leptin, administered 6h or immediately before MCAo produces values of infarct volume comparable to those observed
invehicle-treatedanimals(a).
##Po0.01versusvehicle(one-wayANOVAfollowedbyDunnett’spost-hoctest;n¼5–6ratsperexperimentalgroup).(b)RepresentativeTTC-
stainedbrainslicesand(c)correspondingvaluesofinfarctareasfromratssubjectedto 24hpermanentMCAoandtreated(s.c.)withvehicle(PBS,1ml/kg)orleptin(1mg/kg)
3hbeforetheinductionofischemia.Ischemicbraindamage(palearea)involvesthebrainregionssuppliedbythemiddlecerebralartery,includingthestriatumandthecortex.
Administration of leptin reduces ischemic brain damage in perifocal regions such as the medial caudate–putamen and the motor cortex. *Po0.05 and **Po0.01 versus
corresponding brain section of vehicle-treated animals (Student’s t test, n¼6 rats per experimental group)
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Cell Death and Diseasethose observed at 3h in both the vehicle and leptin
groups (Figure 3). Thus, Akt phosphorylation transiently
increases following ischemic brain insult whereas STAT3
phosphorylation progressively increases up to 24h; further,
p-STAT3 immunoreactivity at 24h after MCAo is enhanced
also in the contralateral brain cortex (Figure 3). Leptin does
not affect the time course of STAT3 and Akt phosphorylation
induced by ischemia but it selectively enhances Akt
phosphorylation 3h after MCAo and STAT3 phosphorylation
24h after ischemia (Figure 3).
Upon tyrosine phosphorylation triggered by diverse stimuli,
including growth factors, cytokines and hormones, STAT3
dimerizes and translocates to the nucleus to induce gene
transcription.
11 Therefore, under the present experimental
conditions, we determined whether or not neuroprotection
afforded by leptin was associated with changes of nuclear
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Figure2 (a)Braininfarctvolumeassessed3and7daysafterpermanentMCAoinratstreated(s.c.)withvehicle(PBS,1ml/kg)orleptin(1mg/kg)3hbeforetheinduction
of ischemia.
#Po0.05 and
##Po0.01 versus corresponding brain section of vehicle-treated animals (Student’s t test, n¼4–6 rats per experimental group). (b) Neuroscore
and (c) body weight measured for 7 consecutive days after permanent MCAo in rats treated (s.c.) with vehicle (PBS, 1ml/kg) or leptin (1mg/kg) 3h before the induction of
ischemia. *Po0.05 versus corresponding score in vehicle-injected animals (Student’s t test, n¼4 rats per experimental group)
Figure 3 Changes in STAT3 and Akt phosphorylation following focal cerebral ischemia as determined by western blot analysis of phospho-STAT3 (Tyr705; p-STAT3),
totalSTAT3,p-Akt(Ser473;p-Akt)andtotalAktperformedonbraincorticalhomogenatesfromtheipsilateral(I)andcontralateral(C)cortexofratstreatedwithvehicle(Veh)or
leptin(Lept)andkilled3or24hafterMCAo.Theresultsarerepresentativeofthreeindependentexperiments.Histogramsshowtheresultsofthedensitometricanalysisofthe
autoradiographic bands; *Po0.05 and ***Po0.001 versus contralateral (C) side.
#Po0.05 versus Sham 3h
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Cell Death and Diseasep-STAT3 levels in the brain cortex from rats subjected to
permanent focal ischemia.
Phosphorylated STAT3 was faintly detectable in the
nuclear and cytosolic fractions from contralateral cerebral
cortex after 3h MCAo. Interestingly, immunoreactivity for
p-STAT3wasenhancedinthenuclear,butnotinthecytosolic,
fraction from the contralateral cortex 24h after occlusion
(Figure 4). Ischemic insult signiﬁcantly increased levels of
STAT3 phosphorylation in both the cytosolic and nuclear
fractions of the ipsilateral, ischemic brain cortex 3h after
MCAo (Po0.05 versus contralateral) and these further
increased in the nuclear (Po0.001 versus 3h) but not in the
cytosolic fraction of ischemic cortex 24h after occlusion.
A similar trend was observed in rats pretreated with leptin
(Figure 4); however, in comparison with vehicle-treated
animals, leptin further increased STAT3 phosphorylation in
the nuclear fraction (Po0.01) 3h after MCAo and in the
cytosolic fraction (Po0.01) 24h after ischemia (Figure 4).
Figure 4 Changes in STAT3 and Akt phosphorylation following focal cerebral ischemia as determined by western blot analysis of phospho-STAT3 (Tyr705; p-STAT3),
total STAT3, p-Akt (Ser473; p-Akt) and total Akt performed on the cytosolic and nuclear fractions of brain cortical homogenates from the ipsilateral (I) and contralateral
(C) cortex of rats treated with vehicle (Veh) or leptin (Lept) and killed 3 or 24h after MCAo. The results are representative of three independent experiments. Histograms
show the results of the densitometric analysis of the autoradiographic bands; *Po0.05, **Po0.01 and ***Po0.001 versus contralateral (C) side.
yPo0.05 and
yyPo0.01
(Leptin versus Vehicle). 1Po0.05, 11Po0.01 and 111Po0.001 (3h versus 24h)
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Cell Death and Diseasep-Akt immunoreactivity was detected in the cytosolic and
nuclear fractions from contralateral side and sham-operated
animals brain cortex at both 3 and 24h after MCAo (Figure 4).
Akt phosphorylation enhanced in both the cytosolic and
nuclear fractions from the ischemic cortex 3h after ischemia
but it no further increased after 24h (Figure 4); nonetheless,
compared with the contralateral cortex, higher levels
(Po0.05) of Akt phosphorylation were reported in the nuclear
fraction from the ischemic cortex 24h after MCAo (Figure 4).
Leptin does not affect the time course of Akt phosphorylation
induced by ischemia but it signiﬁcantly (Po0.05) enhanced
Akt phosphorylation in the nuclear fraction 24h after ischemia
(Figure 4).
Immunoﬂuorescence analysis of p-STAT3 expression
conﬁrmed that this mediator is barely detectable in sham-
operated animals (data not shown); whereas it signiﬁcantly
increases in the brain of rats subjected to permanent MCAo
with a different regional and cellular pattern depending on the
stage of the insult. In fact, after 3h permanent MCAo,
p-STAT3 immunoreactivity was signiﬁcantly increased in the
peri-infarct regions of the ipsilateral hemisphere, namely the
ventralstriatumandthemotorcortex(Figure5e)ascompared
Figure 5 Double p-STAT3/NeuN (a–l) and p-STAT3/GFAP (m–t) immunoreactivity in the contralateral (C) and ipsilateral (I) motor (a–p) and frontal (q–t) cortices of rats
subjected to 3h permanent MCAo. Leptin (1mg/kg, s.c.) or vehicle (PBS, 1ml/kg) were administered 3h before the induction of ischemia. Phospho-STAT3 expression in the
contralateral hemisphere of leptin-treated rats was not signiﬁcantly different from the contralateral hemisphere of vehicle-injected animals shown in panel (a). Nuclei were
counterstained with 40,6-diamidino-2-phenylindole (DAPI). Scale bars¼200mm( a–l) and 100mm( m–t)
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Cell Death and Diseasewith the contralateral hemisphere (Figure 5a). Moreover, at
this stage of the insult, p-STAT3 immunoreactivity was also
detected in the meninges and in the periventricular areas of
the ipsilateral hemisphere, and in the external layer of the
contralateralmotorcortex(Figures5a–d).Inthecoreregionof
the striatum, p-STAT3 was only detected in intravascular cells
(data not shown). In the cortex, p-STAT3 increased in non-
neuronal cells, as shown by the lack of merging with the NeuN
neuronal marker (Figures 5c, g and k), most of which appear
to be astrocytes as demonstrated by the colocalization
with the astrocytic marker glial ﬁbrillary acidic protein
(GFAP; Figures 5o and s). Interestingly, pretreatment with
leptin (1mg/kg, s.c., 3h before MCAo) signiﬁcantly
increased p-STAT3 expression in the cortical penumbra
(Figures 5i versus e), and, in particular, in the nuclei of
astrocytes localized in the motor cortex (Figure 5o) and in the
internal layers of the frontal cortex (Figure 5s).
An increase of p-STAT3 immunoreactivity after leptin
pretreatmentwasalsoobservedinthecortexofratssubjected
to 24h permanent MCAo (Figure 6). At this stage of the insult,
the expression of p-STAT3 was mainly observed in the
neuronsandother(probablymicroglial)cellsoftheperi-infarct
regionofthemotorcortex(Figures6a–h);whereas,inthecore
region of the parietal cortex, p-STAT3 was only expressed
in non-neuronal (probably microglial) cells (Figures 6m–p).
By contrast, in the internal layer of the frontal cortex, a clear
co-localisation of p-STAT3 with the astrocytic marker GFAP
was observed (Figures 6q–t).
Figure 6 Double p-STAT3/NeuN (a–p) and p-STAT3/GFAP (q–t) immunoreactivity in the ipsilateral motor (a–h), parietal (i–p) and frontal (q–t) cortices of rats subjected
to 24h permanent MCAo. Leptin (L, 1mg/kg, s.c.) or vehicle (V, PBS, 1ml/kg) were administered 3h before the induction of ischemia. Nuclei were counterstained with
40,6-diamidino-2-phenylindole (DAPI). Scale bars¼100mm
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Cell Death and DiseaseTissue inhibitor of matrix metalloproteinases-1 (TIMP-1) is
one of STAT3’s target genes, which has been shown to be
induced by leptin in vitro. TIMP-1 expression is barely
detectable in the cortical brain tissue from rats subjected to
3h MCAo or sham operation (data not shown); however,
expression of TIMP-1 signiﬁcantly enhances in the ipsilateral
cortex 24h after permanent MCAo (Figure 7). As shown in
Figure 7, leptin almost doubled cortical TIMP-1 expression
induced by MCAo in the rat.
Discussion
Our data demonstrate that systemic, acute, pretreatment with
leptin reduces the brain infarct damage and neurological
deﬁcit produced by permanent focal cerebral ischemia in the
rat. Neuroprotection is long lasting and seems to occur via
modulation of STAT3 phosphorylation. In fact, the early
enhancement of nuclear p-STAT3 induced by leptin in the
astrocytes of the ischemic penumbra may contribute to a
beneﬁcial effect of these cells on the evolution of tissue
damage. In addition, the elevation of p-STAT3 induced by
leptin in the neurons after 24h MCAo is associated with an
increased expression of TIMP-1 in the cortex, suggesting
its possible involvement to the neuroprotection exerted by the
adipokine.
Previous ﬁndings have demonstrated neuroprotection by
leptin against ischemic brain injury. In fact, the adipokine
protects rat primary cortical neurons against death induced by
oxygen–glucose deprivation (OGD) via the ERK 1/2 signaling
pathway,
5 and mouse cortical neurons exposed to OGD via
the induction of the expression of the anti-apoptotic c-Rel
target gene Bcl-xL.
10 In vivo, neuroprotection by leptin was
observed in different ischemic models, including global and
focal cerebral ischemia. Exogenous administration of this
adipokine provides neuroprotection in mice subjected to
transient
5 or permanent
10 occlusion of the middle cerebral
artery, whereas little information is available in the rat.
Our ﬁndings represent the ﬁrst evidence of neuroprotection
byleptininaratmodelofpermanentMCAoandareconsistent
with previous observations documenting neuroprotection by
leptin under similar experimental conditions in mice.
10 More-
over, we have extended these previous ﬁndings by demon-
strating that the neuroprotection provided by an acute
treatment with leptin is long lasting as it produces a signiﬁcant
reduction of the infarct volume and neurological deﬁcit up to
7 days after the induction of ischemia in the rat.
According to Zhang et al.,
5 we did not ﬁnd signiﬁcant
changes in the CBF after leptin treatment, excluding
the possibility that hemodynamic modiﬁcations mediate
the neuroprotective effect of this adipokine. Although
acute administration of pharmacological doses of leptin
(10–1000m/kg) increases the plasma concentration of
nitric oxide metabolites and of its second messenger,
cGMP,
11studiesperformedinconsciousanimalssuggestthat
leptin-induced endothelial nitric oxide has little, if any,
hemodynamic role.
12
We failed to observe any protective effect of leptin when it
was administered at onset of MCAo. The lack of protection
under a similar treatment schedule was also reported in mice
subjected to transient MCAo.
13 By contrast, Zhang et al.
5
observed neuroprotection following treatment with leptin up to
90min after the beginning of reperfusion in mice. The
apparent discrepancy between this latter evidence and
our data may stem from the different experimental model
and animal species used, the permanent MCAo in the rat
being insensitive to leptin post-treatment.
Clinical studies suggest that elevated circulating leptin
levels, such as those frequently found in obesity, are
independently associated with elevated cardiovascular risk.
Accordingly, large population-based studies suggest a strong
positive association between increased plasma leptin levels
and stroke.
14–16 Indeed, experimental studies have shown
that leptin exerts prothrombotic effects in vivo.
17
In addition to clinical data that have indicated increased risk
of stroke in obese individuals,
18 recent studies have shown
that the severity of brain damage is increased after experi-
mental stroke in obese rodents
19 and this effect appears to
be independent of leptin deﬁciency. In fact, the increased
incidence of hemorrhagic transformation and the exacerba-
tion of inﬂammatory responses and ischemic brain damage
observed in obese ob/ob mice were not affected by systemic
treatment with leptin.
13,19 As obesity may be a consequence
of leptin resistance, the latter likely resulting from an impaired
transport of this hormone across the blood brain barrier,
20 it is
intriguing to speculate that the reduced access of leptin to the
brain may be responsible for the increased susceptibility of
obese subjects to the ischemic insult. Moreover, Valerio
et al.
10 have shown that leptin mRNA levels and protein
expression increase in the microglia/macrophages populating
the perilesional cerebral cortex of mice subjected to perma-
nent MCAo. Indeed, this may represent an endogenous
Figure 7 Changes in TIMP-1 expression following focal brain ischemia as
determined by western blot analysis performed on brain cortical homogenates from
the ipsilateral (I) and contralateral (C) cortex of rats treated with vehicle (Veh) or
leptin (Lept) and killed 24h after MCAo. The results are representative of three
independent experiments. Histograms show the results of the densitometric
analysis of the autoradiographic bands; **Po0.01 and ***Po0.001 versus
contralateral (C) side.
yyPo0.01 (Leptin versus Vehicle)
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Cell Death and Disease(repair) mechanism activated either peripherally or locally to
rescue the damaged tissue, although further studies are
needed to clarify this hypothesis.
In order to evaluate the molecular mechanisms involved in
neuroprotection, previous studies have primarily focused
on the effects of leptin on injured neurons, arguing that an
increase of pERK expression
5 or the induction of c-Rel-
dependenttargetgenes
10inthesecellsunderliethe beneﬁcial
effects of the hormone against an ischemic insult.
Surprisingly, although being a major mediator of ObR
transductionpathwayinthebrain,
9STAT3anditscontribution
to leptin neuroprotection under ischemic conditions was only
marginally studied. Levels of p-STAT3 measured by western
blotting in whole tissue homogenates from brain of ischemic
rodents were only slightly affected by leptin treatment,
5
probably because of the different cellular (glia versus
neurons) source and subcellular compartmentalization of this
mediator. This represents a major limitation of previous
studies, as activation of STAT proteins implicates their
phosphorylation and nuclear translocation to induce gene
transcription. By using a cell fractionation approach, com-
bined with immunoﬂuorescence, here we have demonstrated
that cell-speciﬁc STAT3 activation may represent a pivotal
mechanism recruited by leptin to afford neuroprotection.
Our data demonstrate that p-STAT3 is signiﬁcantly ele-
vated in the ipsilateral brain hemisphere after permanent
MCAo, being its nuclear translocation increased with the
progression of the insult. Neuroprotection by leptin is
associated with a further elevation of p-STAT3 in the nuclear
(at 3h MCAo) and cytosolic (at 24h MCAo) fractions of the
ischemic cortex. An increased phosphorylation of STAT3 on
Tyr-705 was reported after either permanent or transient focal
cerebral ischemia.
21,22 Despite some studies have suggested
that phosphorylation of STAT3 might be involved in neuronal
death after cerebral ischemia,
22,23 our data are consistent
with other ﬁndings claiming a protective role.
21,24,25 Indeed,
STAT3 induces the expression of neuroprotective genes,
suchasbcl-2,bcl-xL
26–28andTIMP-1.
29Accordingly,wehave
observed that the increased levels of p-STAT3 produced by
leptin in the ischemic cortex are associated with the elevation
ofTIMP-1expression,suggestingthatthislattermediatormay
underlie the beneﬁcial effects of the adipokine.
More interestingly, we have observed that neuroprotection
by leptin is associated with elevation of p-STAT3 in the nuclei
of the astrocytes of the cortical penumbra, asearly as3h after
permanent MCAo. Previous ﬁndings have demonstrated that
leptin is induced in the brain microglia/macrophages after
stroke
10andglialcells,inturn,expressboththelongandshort
form of the leptin receptor.
6 Astrocytes-expressing ObR may
have a role in the regulation of food intake,
7 and recent
ﬁndings have also suggested that the modulation of astrocytic
activity by leptin is implicated in hypothalamic synaptic
rearrangement.
30
STAT3 is required for complete differentiation of astrocytes
and regulates the expression of GFAP, a hallmark indicator of
astrogliosis, via a STAT-responsive element in the GFAP
promoter.
31,32 The crucial role of STAT3 in the regulation of
astroglial reaction in vivo has been demonstrated in several
experimental models of brain injury, such as following
excitotoxic brain lesions, kainic acid-induced seizures and,
most notably, transient cerebral ischemia.
33 The protective
role of reactive astrocytes in stroke is well documented;
moreover, astrocytes have been suggested to promote
neuronal survival and differentiation.
34 Under ischemic con-
ditions, activation of STAT3 signaling pathway in astrocytes
underlies the neuroprotective effects of cytokines acting
on gp130 receptor, a molecule belonging to the same
(interleukin-6-type cytokine) receptor family as ObR.
8
In line with these previous ﬁndings, our data suggest that
STAT3 activation might contribute to astrocytic activation
under ischemic conditions and, more importantly, the neuro-
protective effect of leptin is due to an early regulation of
reactive astrocytes, via increased STAT3 phosphorylation.
Induction of reactive astrogliosis may thus represent a pivotal
mechanism activated by leptin early after permanent MCAo to
rescue the peripheral territories of the penumbra.
By contrast, 24h after MCAo we observe that elevation of
p-STAT3 does mainly occur in the neurons of the peri-infarct
cortex and in glial cells throughout the ischemic hemisphere.
This is consistent with previous ﬁndings obtained under
conditions of transient MCAo.
21,25,35 More interestingly,
we observe that neuroprotection by leptin is associated with
increased levels of p-STAT3 in the neurons of the cortical
penumbra. Thus, in addition to the early recruitment of a
beneﬁcial astrocytic response, leptin may act directly on the
neurons to promote their survival, probably via elevation of
downstream TIMP-1 expression. Our data are consistent with
the knowledge that STAT3 activation has a beneﬁcial role in
neurons under a variety of brain pathological conditions,
35
including transient focal cerebral ischemia.
24,25 By contrast,
excessive STAT3 activation in microglia–macrophages
has been demonstrated to provide a detrimental effect
after ischemia-reperfusion injury,
23 further suggesting that a
differential cellular activation of this mediator may serve
different functions.
According to previous ﬁndings,
36,37 we have found a
transient enhancement of p-Akt in the ischemic cortex of rats
subjected to pMCAo. Activation of the PI3K/Akt pathway
has been suggested to speciﬁcally occur in the neurons of the
ischemic penumbra and is believed to rescue these cells from
delayed cell death.
36 Notably, the PI3K/Akt pathway is
implicated in leptin signaling in neurons and there is evidence
suggesting a role of JAK2/STAT3 upstream of PI3K/Akt upon
leptin exposure in neurons. Here, we observe that leptin only
transientlymodiﬁes p-Aktlevels intheischemic cortex,having
no effect on the time-course activation of this signaling
pathway during permanent MCAo. Thus, although we cannot
exclude that this pathway may contribute to the neuroprotec-
tion provided by leptin after stroke injury, the effect on STAT3
activation/phosphorylation appears to have a more speciﬁc
and signiﬁcant role.
In conclusion, our ﬁndings demonstrate that the neuro-
protection exerted by leptin in a rat model of permanent focal
cerebral ischemia is associated with modulation of STAT3
phosphorylation in different cellular populations of the injured
brain. In particular, by increasing nuclear translocation of
p-STAT3, leptin may promote a beneﬁcial astrocytic reaction
intheischemicpenumbratriggeredasearlyasfewhoursafter
the insult. By contrast, at later stages, the adipokine elevates
p-STAT3inneuronsandthisiscoincidentwiththeinductionof
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mechanisms are associated with a long-lasting neuroprotec-
tion after an acute treatment with leptin, being both the infarct
volume and the neurological deﬁcit produced by permanent
MCAo signiﬁcantly reduced up to 7 days after the insult.
Together with the already established safety of leptin
treatment in human,
38 these data underscore the therapeutic
potential of this adipokine for the treatment of ischemic brain
injury.
Methods
Focal cerebral ischemia and drug treatments. Adult male Wistar rats
(Charles River, Calco, Como, Italy) were housed under controlled environmental
conditions with ambient temperature of 221C, relative humidity of 65% and 12h
light:12h dark cycle, with free access to food and water.
Brain ischemia was induced by occlusion of the middle cerebral artery in rats
weighing 280–320g by intraluminal ﬁlament, using a relatively non-invasive
technique as described previously.
39,40 Brieﬂy, rats were anaesthetized with 5%
isoﬂurane in air, and were maintained with the lowest acceptable concentration of
the anesthetic (1.5–2%). Body temperature was measured with a rectal probe and
wasmaintainedat371Cduringthesurgicalprocedurewithaheatingpad.Underan
operating microscope, the external and internal right carotid arteries were exposed
through a neck incision. The external carotid artery was cut B3mm above the
common carotid artery bifurcation and a silk suture was tied loosely around the
externalcarotidstump.A silicone-coatednylonﬁlament(diameter:0.37mm, Doccol
Corporation, Redlands, CA, USA) was then inserted into the external carotid artery
and gently advanced into the internal carotid artery, B18mm from the carotid
bifurcation,untilmildresistancewasfelt,thereby,indicatingocclusionoftheoriginof
the middle cerebral artery in the Willis circle. The silk suture was tightened around
the intraluminal ﬁlament to prevent bleeding. The wound was then sutured and
anesthesia discontinued.
During surgery, CBF was monitored over the cerebral cortex of the ischemic
hemisphere, corresponding to the supply territory of the middle cerebral artery, by
lased-Doppler ﬂowmetry (Periﬂux System 5000, Perimed, Stockholm, Sweden).
To this aim, a ﬂexible laser-Doppler probe was glued onto the parietal bone (2mm
posterior and6mmlateralfrombregma)andlocalCBFwas continuouslymeasured
from 15min before the onset of ischemia until 10min after MCAo, keeping the
animalunderisoﬂuraneanesthesia.Changesinregional CBFduringischemiawere
calculated as a percentage of the preischemic basal values.
Sham rats were exposed to the same surgical procedure without occlusion of
MCA.
Recombinant rat leptin (ProSpec-Tany TechnoGene Ltd., Rehovot, Israel;
1mg/kg) or vehicle (PBS, 1ml/kg) were administered s.c. 6h, 3h or immediately
before MCAo. To assess the effect of leptin on body weigh, rats were weighed
immediately before surgery and, then, daily before killing.
All the experimental procedures were carried out in accordance with the
European Community Council Directive of 24 November 1986 (86/609/EEC),
included in the DM 116/1992 of the Italian Ministry of Health.
Neuropathology and quantiﬁcation of ischemic damage. After
24h permanent MCAo, the cerebral infarct volume was evaluated by the 2,3,
5-triphenyltetrazolium chloride (TTC) staining technique. Brieﬂy, rats were killed by
decapitation and the brains were rapidly removed from the skull. Eight serial
sectionsfrom each brain were cut at 2-mm intervals from the frontal poleusing a rat
brain matrix (Harvard Apparatus, Holliston, MA, USA). To measure ischemic
damage, brain slices were stained in a solution containing 2% TTC in saline, at
371C. After 10min incubation, the slices were transferred to 10% neutral buffered
formaldehyde and stored at 41C before analysis.
To evaluate infarct volume 3 or 7 days after MCAo, brains were removed from
theskullandimmediatelyfrozeninisopentanecooledwithdryice.Eight20mm-thick
coronal sections were cut, at 2mm intervals from the frontal pole, using a cryostat,
and stained with cresyl violet.
Images of TTC- or cresyl violet-stained sections were captured by a digital
scanner and analyzed using an image analysis software (ImageJ, version 1.30, US
National Institutes of Health, Bethesda, MD, USA). Infarct volume (mm
3) was
determined by summing the infracted (pale) areas of the eight coronal tissue slices
and multiplying the obtained value by the interval thickness between sections
(2mm).
Neurological examination. Neurological deﬁcits in rats were examined
daily, up to 7 days after permanent MCAo, by an investigator (FP) blinded to the
treatment. The deﬁcits were scored on a modiﬁed scoring system based on that
developed by Longa et al.,
39 as follows: 0, no deﬁcit; 1, failure to fully extend the
contralateral forelimb; 2, reduced resistance to a lateral push; 3, circling to
contralateral side; 4, falling to contralateral side; 5, no spontaneous walking with
depressed level of consciousness.
Preparation of brain tissue homogenates. Individual cortical tissue
samples of sham-operated rats and of rats subjected to permanent focal cerebral
ischemia (n¼3 per group) were rapidly dissected out and homogenized in a glass
homogenizer using six volumes of ice-cold lysis buffer containing 50mM Tris-HCl,
pH 7.5, 150mM NaCl, 2mM EDTA, 2mM EGTA, 1% Triton, 1nM okadaic acid, a
cocktail of protease inhibitors (code P8340, Sigma, Milan, Italy) and a cocktail of
phosphatase inhibitors (code 524625, Calbiochem, La Jolla, CA, USA); samples
were then centrifuged at 10000 g for 15min at 41C. Protein concentration in
the supernatant was determined by the DC protein assay (Bio-Rad Laboratories,
Milan, Italy).
Subcellular fractionation. The cytosolic and nuclear protein extracts were
prepared from rat brain cortices dissected 3 and 24h after ischemia or sham
operation (n¼3 per group). The tissues were ﬁrst homogenized in an ice-cold
hypotonicbuffercontaining320mMsucrose,10mMTris-HCl,pH7.4, 1nMokadaic
acid, a cocktail of protease inhibitors (code P8340, Sigma) and a cocktail of
phosphatase inhibitors (code 524625, Calbiochem) and the homogenates
were centrifuged twice at 1300 for 5min to pellet nuclei. The supernatants
were centrifuged at 17000 g for 10min to pellet the mitochondria; the post-
mitochondrial supernatants were centrifuged at 100000 g for 1h and the high-
speed supernatant retained as a cytosolic fraction. The crude nuclear pellets were
resuspendedin0.35mlofsucrosebuffer,subjectedtothreefreeze-thawcyclesand
then soniﬁed for 30s on ice; the nuclear suspensions were then centrifuged at
40000 g for 30min to remove insoluble material. Protein concentration was
determined by using the Bio-Rad DC protein assay (Bio-Rad Laboratories).
All procedures were performed at 41C.
Western blot analysis. Proteins were resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and electrotransferred to nitrocellulose
membranes (Optitran BA-S 83, Schleicher & Schuell Bioscence, Dassel,
Germany). Primary antibodies were incubated overnight at 41C followed by a
horseradish peroxidase-conjugated secondary antibody for 1h at room
temperature. Immunoreactivity was visualized by enhanced chemiluminescent
detection (Amersham Biosciences, GE Healthcare, Milan, Italy) and exposure to
X-ray ﬁlms (Hyperﬁlm ECL, Amersham Biosciences). Autoradiographic ﬁlms were
scanned and densitometric analysis was carried out using Quantiscan software
(Biosoft, Cambridge, UK). The following primary antibodies were used: a rabbit
polyclonal antibody for p-STAT3 (Tyr705) at 1:1000 dilution (code 9131, Cell
SignalingTechnology,Beverly,MA,USA),arabbitpolyclonalantibodyforSTAT3at
1:1000 dilution (code 9132, Cell Signaling Technology), a rabbit polyclonal
antibody for p-Akt at 1:1000 dilution (code 9271, Cell Signaling Technology), a
rabbit polyclonal antibody for Akt at 1:2000 dilution (code 9272, Cell Signaling
Technology), a mouse monoclonal antibody for TIMP-1 at 1:200 dilution (code
MAB13428, Chemicon International Inc., Temecula, CA, USA), a mouse
monoclonal anti-actin antibody at 1:2000 dilution (clone AC-40; Sigma).
Immunohistochemistry. After 3 and 24h of MCAo, animals were
anesthetized with sodium pentobarbital (60mg/kg, intraperitoneal) and perfused
through the heart with saline (0.9% NaCl) followed by 4% paraformaldehyde in
phosphate buffer (PB; 0,1M; pH 7.4), containing 50mM NaF. Each brain was
rapidly removed, post-ﬁxed in the same ﬁxative for 2h and, after three washes in
PB, transferred to 30% sucrose in PB solution at 41C until it sank. A volume of
40mm-thickcoronalbrainsections,attheleveloftheMCAterritory(1.7to 3.3mm
from Bregma), were obtained using a freezing microtome and collected in PB.
For p-STAT immunostaining, tissue slices were pre-treated with 1% NaOH and
1% H2O2 in H2O for 20min, 0.3% glycine (in PB) for 10min, and 0.03% sodium
dodecyl sulfate (in PB) for 10min. After two washes in PB, the sections were
pre-incubated for 1h in blocking solution (3% normal donkey serum, 0.2% Triton
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incubated for 24h at 41C. Colocalization studies were performed as described
previously,
40 using a combination of the following primary antibodies: rabbit
polyclonal anti-p-STAT3 (1:200 dilution; Tyr705, Cell Signaling Technology),
mouse anti-GFAP (anti-GFAP; 1:200 dilution; code AB5804, Merck Millipore,
Milan, Italy) to label astrocytes, or mouse anti-NeuN (anti-neuronal nuclei; 1:200
dilution; MAB377, Chemicon International) to label neurons.
Thereafter, sections were incubated for 2h at room temperature in a solution
containing an appropriate mixture of the corresponding secondary antibodies:
Alexa Fluor 488 donkey anti-rabbit and Alexa Fluor 594 donkey anti-mouse IgG
(1:400 dilution; Molecular Probes; Invitrogen, Milan, Italy). Finally, nuclei were
counterstained with 40,6-diamidino-2-phenylindole (1:500; Sigma-Aldrich, Milan,
Italy), and the sections were mounted on gelatin-coated slides, air-dried and
coverslipped with Fluoromount (Diagnostic BioSystems, Pleasanton, CA, USA).
To rule out interference of non-speciﬁc staining, control experiments were
performed under conditionsidentical to those described above, with the omission of
primary antibody.
Immunostaining was examined under a ﬂuorescence microscope (Leica
DMI6000B, Leica Microsystems Srl, Milan, Italy) equipped with a high-resolution
digital camera (Leica DFC350FX) and a dedicated software (LAS AF6000) for
image analysis and deconvolution.
Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements. Partial ﬁnancial support from the Italian Ministry of
Health (RF05.105 to MTC and Ricerca Corrente 2009 to CT) and from the Italian
Ministry of University and Research (PRIN prot. 20089BARSR_004 to GB) is
gratefully acknowledged.
1. Harvey J. Leptin: a diverse regulator of neuronal function. J Neurochem 2007; 100:
307–313.
2. Bouret SG. Neurodevelopmental actions of leptin. Brain Res 2010; 1350: 2–9.
3. Tang BL. Leptin as a neuroprotective agent. Biochem Biophys Res Comm 2008; 368:
181–185.
4. Elmquist JK, Bjørbaek C, Ahima RS, Flier JS, Saper CB. Distributions of leptin receptor
mRNA isoforms in the rat brain. J Comp Neurol 1998; 395: 535–547.
5. Zhang F, Wang S, Signore AP, Chen J. Neuroprotective effects of leptin against ischemic
injury induced by oxygen-glucose deprivation and transient cerebral ischemia. Stroke
2007; 38: 2329–2336.
6. Hosoi T, Okuma Y, Nomura Y. Expression of leptin receptors and induction of IL-1beta
transcript in glial cells. Biochem Biophys Res Commun 2000; 273: 312–315.
7. Cheunsuang O, Morris R. Astrocytes in the arcuate nucleus and median eminence that
take up a ﬂuorescent dye from the circulation express leptin receptors and neuropeptide Y
Y1 receptors. Glia 2005; 52: 228–233.
8. Baumann H, Morella KK, White DW, Dembski M, Bailon PS, Kim H et al. The full-length
leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Natl
Acad Sci USA 1996; 93: 8374–8378.
9. Vaisse C, Halaas JL, Horvath CM, Darnell Jr JE, Stoffel M, Friedman JM. Leptin activation
of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet
1996; 14: 95–97.
10. Valerio A, Dossena M, Bertolotti P, Boroni F, Sarnico I, Faraco G et al. Leptin is induced in
the ischemic cerebral cortex and exerts neuroprotection through NFkappaB/c-Rel-
dependent transcription. Stroke 2009; 40: 610–617.
11. Beltowski J, Wojcicka G, Borkowska E. Human leptin stimulates systemic nitric oxide
production in the rat. Obes Res 2002; 10: 939–946.
12. Mitchell JL, Morgan DA, Correia ML, Mark AL, Sivitz WI, Haynes WG. Does leptin
stimulate nitric oxide to oppose the effects of sympathetic activation? Hypertension 2001;
38: 1081–1086.
13. McColl BW, Rose N, Robson FH, Rothwell NJ, Lawrence CB. Increased brain
microvascular MMP-9 and incidence of haemorrhagic transformation in obese mice
after experimental stroke. J Cereb Blood Flow Metab 2010; 30: 267–272.
14. So ¨derberg S, Stegmayr B, Stenlund H, Sjo ¨stro ¨m LG, Agren A, Johansson L et al.
Leptin, but not adiponectin, predicts stroke in males. J Intern Med 2004; 256: 128–136.
15. Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F, Gami AS, Sert Kuniyoshi FH,
Wolk R et al. Relation of increased leptin concentrations to history of myocardial infarction
and stroke in the United States population. Am J Cardiol 2007; 100: 234–239.
16. Liu J, Butler KR, Buxbaum SG, Sung JH, Campbell BW, Taylor HA. Leptinemia and its
association with stroke and coronary heart disease in the Jackson Heart Study. Clin
Endocrinol (Oxf) 2010; 72: 32–37.
17. Konstantinides S, Scha ¨fer K, Loskutoff DJ. The prothrombotic effects of leptin possible
implications for the risk of cardiovascular disease in obesity. Ann NY Acad Sci 2001; 947:
134–141.
18. Winter Y, Rohrmann S, Linseisen J, Lanczik O, Ringleb PA, Hebebrand J et al.
Contribution of obesity and abdominal fat mass to risk of stroke and transient ischemic
attacks. Stroke 2008; 39: 3145–3151.
19. Terao S, Yilmaz G, Stokes KY, Ishikawa M, Kawase T, Granger DN. Inﬂammatory
and injury responses to ischemic stroke in obese mice. Stroke 2008; 39: 943–950.
20. Banks WA. The blood-brain barrier as a cause of obesity. Curr Pharm Des 2008; 14:
1606–1614.
21. Suzuki S, Tanaka K, Nogawa S, Dembo T, Kosakai A, Fukuuchi Y. Phosphorylation of
signal transducer and activator of transcription-3 (Stat3) after focal cerebral ischemia in
rats. Exp Neurol 2001; 170: 63–71.
22. Wen TC, Peng H, Hata R, Desaki J, Sakanaka M. Induction of phosphorylated-STAT3
following focal cerebral ischemia in mice. Neurosci Lett 2001; 303: 153–156.
23. Satriotomo I, Bowen KK, Vemuganti R. JAK2 and STAT3 activation contributes to
neuronal damage following transient focal cerebral ischemia. J Neurochem 2006; 98:
1353–1368.
24. Yamashita T, Sawamoto K, Suzuki S, Suzuki N, Adachi K, Kawase T et al. Blockade of
interleukin-6 signaling aggravates ischemic cerebral damage in mice: possible
involvement of Stat3 activation in the protection of neurons. J Neurochem 2005; 94:
459–468.
25. Komine-Kobayashi M, Zhang N, Liu M, Tanaka R, Hara H, Osaka A et al. Neuroprotective
effect of recombinant human granulocyte colony-stimulating factor in transient focal
ischemia of mice. J Cereb Blood Flow Metab 2006; 26: 402–413.
26. StephanouA,BrarBK,KnightRA,LatchmanDS.OpposingactionsofSTAT-1andSTAT-3
on the Bcl-2 and Bcl-x promoters. Cell Death Differ 2000; 7: 329–330.
27. Jourdan M, De Vos J, Mechti N, Klein B. Regulation of Bcl-2-family proteins in myeloma
cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like
growth factor 1. Cell Death Differ 2000; 7: 1244–1252.
28. Sepulveda P, Encabo A, Carbonell-Uberos F, Min ˜ana MD. BCL-2 expression is mainly
regulated by JAK/STAT3 pathway in human CD34+ hematopoietic cells. Cell Death Diff
2007; 14: 378–391.
29. Lin S, Saxena NK, Ding X, Stein LL, Anania FA. Leptin increases tissue inhibitor of
metalloproteinase I (TIMP-1) gene expression by a speciﬁcity protein 1/signal transducer
and activator of transcription 3 mechanism. Mol Endocrinol 2006; 20: 3376–3388.
30. Garcı ´a-Ca ´ceres C, Fuente-Martı ´n E, Burgos-Ramos E, Granado M, Frago LM, Barrios V
et al. Differential acute and chronic effects of leptin on hypothalamic astrocyte morphology
and synaptic protein levels. Endocrinology 2011; 152: 1809–1818.
31. TakizawaT,YanagisawaM,OchiaiW,YasukawaK,IshiguroT,NakashimaKetal.Directly
linked soluble IL-6 receptor-IL-6 fusion protein induces astrocyte differentiation from
neuroepithelial cells via activation of STAT3. Cytokine 2001; 13: 272–279.
32. Fukuda S, Kondo T, Takebayashi H, Taga T. Negative regulatory effect of an
oligodendrocytic bHLH factor OLIG2 on the astrocytic differentiation pathway.
Cell Death Diff 2004; 11: 196–202.
33. Justicia C, Gabriel C, Planas AM. Activation of the JAK/STAT pathway following transient
focal cerebral ischemia: signaling through Jak1 and Stat3 in astrocytes. Glia 2000; 30:
253–270.
34. Cordero-Llana O, Scott SA, Maslen SL, Anderson JM, Boyle J, Chowhdury RR et al.
Clusterin secreted by astrocytes enhances neuronal differentiation from human neural
precursor cells. Cell Death Differ 2011; 18: 907–913.
35. Dziennis S, Alkayed NJ. Role of signal transducer and activator of transcription
3 in neuronal survival and regeneration. Rev Neurosci 2008; 19: 341–361.
36. Zhao H, Sapolsky RM, Steinberg GK. Phosphoinositide-3-kinase/Akt survival
signal pathways are implicated in neuronal survival after stroke. Mol Neurobiol 2006; 34:
249–269.
37. Amantea D, Fratto V, Maida S, Rotiroti D, Ragusa S, Nappi G et al. Prevention of
glutammate accumulation and upregulation of phospho-Akt may account for
neuroprotection afforded by bergamot essential oil against brain injury induced by focal
cerebral ischemia in rat. Int Rev Neurobiol 2009; 85: 389–405.
38. Heymsﬁeld SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T et al.
Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled,
dose-escalation trial. JAMA 1999; 282: 1568–1575.
39. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery
occlusion without craniotomy in rats. Stroke 1989; 20: 84–91.
40. Amantea D, Bagetta G, Tassorelli C, Mercuri NB, Corasaniti MT. Identiﬁcation of distinct
cellular pools of interleukin-1b during the evolution of the neuroinﬂammatory response
induced by transient middle cerebral artery occlusion in the brain of rat. Brain Res 2010;
1313: 259–269.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under the Creative Commons Attribution-Noncommercial-No
DerivativeWorks3.0Unported License. To viewacopyofthis license,
visit http://creativecommons.org/licenses/by-nc-nd/3.0/
Leptin neuroprotection in permanent MCAo
D Amantea et al
10
Cell Death and Disease